What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

Current radiopharmaceuticals

Volumn 6, Issue 2, 2013, Pages 96-105

  Slavikova, K ^a   Montravers, F ^b   Treglia, G ^b   Kunikowska, J ^b   Kaliska, L ^b   Vereb, M ^b   Talbot, J N ^b   Balogova, S ^b  

^a Faculty of Natural Sciences   (Slovakia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; AMINE; DOPA; FLUORINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE BLOOD LEVEL; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR;

ANALOGS AND DERIVATIVES; BONE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; ECONOMICS; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIATION DOSE; SCINTISCANNING; THYROID TUMOR; TUMOR RECURRENCE;

AMINES; BLOOD GLUCOSE; BONE AND BONES; DIHYDROXYPHENYLALANINE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84893829043     PISSN: None     EISSN: 18744729     Source Type: Journal    
DOI: None     Document Type: Review

References (0)